What We Do: Cutting-Edge Healthcare Diagnostics

Home - Diagnostics

What We Do: Cutting-Edge Healthcare Diagnostics

About Randox

You may already be familiar with Randox! Not only do we sponsor the world’s greatest race, the Randox Grand National, we also have a range of sporting partnerships including Team GB, Sheffield United Football Club, Olimpia Milano basketball team and more. Or perhaps you recognise the name as being one of the partners in the UK Government’s testing programme for COVID-19.

Disruptive Innovation in Diagnostics and Healthcare

Randox is dedicated to improving healthcare using innovative diagnostic technologies, for a range of health conditions including heart disease, diabetes, Alzheimer’s disease, cancer and stroke.

Whilst the science is complex, the applications are not. Diagnostic testing takes place every day behind the scenes of GP surgeries, laboratories and hospitals.

Around 70% of all medical decisions are based on laboratory results, and so, not surprisingly, we believe that earlier, more accurate and more accessible diagnostics are the key to improving global health and saving lives.

The Future of Healthcare

We are significantly increasing our UK High Street presence, using the unique national coronavirus testing infrastructure and capacity we invested in during the pandemic to deliver a new range of preventative health checks. Expansion plans will see up to 20 new Randox Health clinics operating in the UK and Northern Ireland by the end of the year. The clinics will provide easy access for millions to a range of diagnostic tests for vitamin deficiencies, hormone imbalances, inherited/genetic conditions and key health concerns including heart, liver and kidney conditions.

Key to the unique range of diagnostic testing available at our growing network of clinics is the testing technologies, facilities and comprehensive, nationwide distribution network rapidly developed by Randox Laboratories to play a key role in meeting the sudden national demand for Covid-19 PCR tests. At the height of the pandemic emergency, Randox were the only laboratory in the UK and Northern Ireland to process over 100,000 PCR tests per day, saving thousands of lives.

Now, with millions of people having become accustomed to regular testing through the pandemic, Randox is combining that familiarity with its own unique Covid-19 experience and infrastructure to deliver real, affordable and preventative healthcare through early diagnostic testing on the High Street.


“Randox believes that in harnessing the achievements of during the pandemic we can help the shift away from the traditional model of sickness management to a new era of truly preventative healthcare. This will benefit individuals and society by improving patient outcomes and considerably reducing the burden on our vital and hard-pressed clinical services” (Randox founder and Managing Director – Dr Peter FitzGerald).

Frequently Asked Questions?

  • What is the vision of Randox?

    The Randox ethos of improving healthcare, which drove our Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of our turnover is reinvested in research and development to enable our scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.

    We have also spent more than £220 million developing our patented Randox Biochip.  This state-of-the-art biochip technology has revolutionised the diagnostics industry because it allows multiple tests to be carried out from a single, undivided patient sample on a single testing platform.

  • When and why was Randox established?

    Our Managing Director Dr FitzGerald established Randox in 1982 in County Antrim, Northern Ireland, to address the need for accurate and readily available diagnostic tests to improve patient diagnosis.  At that time, doctors only conducted a handful of tests per patient, but now, more than 40 years later, Randox has developed and improved hundreds of tests, with hundreds more in development.

  • What products and service do Randox offer?

    Randox has a broad range of products and services that offer a comprehensive insight into patient diagnosis to facilitate more effective disease management and treatment.

    Our clinical product offering includes diagnostic reagents, quality control, and clinical chemistry analysers.

    Our patented Randox Biochip Technology and associated Immunoassay analysers also have applications for forensic toxicology, food diagnostics, and workplace drug testing.

    Our Randox Health clinics offer a range of health checks across general health, sexual health, respiratory health and more. 

  • Who and where are Randox customers?

    Randox’s focus has traditionally been on healthcare providers, so we have placed our products and services in hospitals, clinics, research and molecular laboratories, food testing, forensic toxicology, life sciences and veterinary laboratories.

    With the establishment of our consumer brand, Randox Health, we also offer our innovative tests directly to the consumer in our Randox Health clinics, located across the UK including London, Liverpool, Manchester, Birmingham, Glasgow, Edinburgh, Holywood and Crumlin.

    We have ambitious plans to roll out a number of new clinics across the United Kingdom and internationally, over the coming months and years.

  • What is the size of the company?

    Our company has grown from a small team of two scientists, to over 3300 employees of 44 nationalities, including 650 research scientists and engineers.

     

  • Where are Randox headquartered and what is the geographical reach?

    Our headquarters are in Crumlin, in County Antrim, Northern Ireland – close to Belfast International Airport.  However, we are a global company and currently have offices and distribution outlets in 145 countries, with manufacturing and R&D capabilities in 4 jurisdictions across 3 continents.

    We are currently relocating our headquarters to the Randox Science Park in Antrim; a £161 million project which will accelerate the development of new products into a wide range of clinical needs, including various cancers, stroke, heart disease and neurodegenerative disorders.

    We are very proud of our global penetration – today, approximately 5% of the world’s population receives medical diagnoses using products from Randox.  That equates to about 400 million people. We also supply 15% of the world’s cholesterol tests, so if you’ve ever had your cholesterol checked,  then there’s a high chance it could have been performed using a Randox product!

  • What are the biggest issues within the health sector?

    Our key observation across the globe is that within healthcare the pressure on resources means there is a focus on the “management of sickness,” rather than preventative care. 

    We know that a focus on early diagnosis and preventative care will improve patient outcomes and reduce the burden on healthcare systems.  Making that paradigm shift is a major challenge.  

    That’s why Randox Health was established – to allow the consumer direct access to our innovative technologies so that they can take control of their health and make appropriate lifestyle changes BEFORE disease manifests and symptoms occur.

  • What is Randox doing in the fight against COVID-19?

    To find out more about our test and testing services for COVID-19, visit our COVID-19 FAQ page by clicking here.

Want to know more?

Contact us or visit our dedication to quality webpage.

Our History

Company Values

Our Accreditations


Randox to deliver £10m investment for major UK research project

About Randox       News        Contact Us

Diagnostics and personalised health company Randox to deliver £10m investment for major UK research project Our Future Health

Randox, the Northern Ireland-based diagnostics and personalised health company, has today been announced as one of four new industry partners in the Our Future Health (OFH) programme, which will be the UK’s largest ever health research programme.

Randox will deliver a £10m investment in the programme, which will discover and develop new methods of prevention, early detection and treatment of diseases and health conditions.

The company is one of four new partners who will deliver a total of £40m to OFH. They join 10 additional life sciences companies that were previously announced as funding partners in January 2022. As well as its £10m investment, Randox will contribute its world-leading expertise to the programme. Its network of 20 High Street clinics, including those in Holywood and Crumlin, will also be available if required to test volunteers from across the UK taking part in the OFH project. The project aims to monitor the long-term health of 5 million volunteers in the coming years, starting this autumn.

Andrew Roddam, Chief Executive of OFH, said: “We are delighted to be announcing a further four industry partners for OFH, who together will provide an additional £40m to further our objective to develop new ways to prevent, detect and treatments enabling people to live healthier lives for longer.  We welcome Randox as one of these partners, knowing their long-term commitment to diagnostics, and look forward to working with them in the months and years ahead.”

OFH has also joined with 16 health research charities, who have endorsed the pilot phase of the programme and are providing valuable support and experience.

Volunteers will be asked to complete an online health questionnaire, give their informed consent to link information from their healthcare records to OFH and donate a small blood sample.

Volunteers are also being asked to give their permission for OFH to contact them in the future to give them the opportunity to take part in follow-on research and to provide personal feedback about their health, should they wish to receive it.

Researchers from across the life sciences community, including academia, industry and the NHS, will be able to apply to study OFH resources as part of their crucial research to accelerate the discovery and development of innovative diagnostics and treatments.

Volunteers’ data will be de-identified and held in ‘trusted research environments’ that meet strict security criteria and an access board, which will include independent experts and members of the public, to ensure OFH resources are only used for health research in the public interest.

Randox Managing Director, Dr Peter FitzGerald said:

“Randox has been engaged from the very outset and is now excited to formally support this world-leading research project, both as a funding member and with our considerable expertise.

“With over 40 years of diagnostic experience, and extensive research capabilities, Randox knows that a personalised approach to the early detection and prevention of disease is not only critical to saving and extending life, but also to improving the quality of our lives. This project will further those critical goals. The ability for participants to receive feedback on their health from the project, and to engage with future research, also promotes Randox’s objective of greater individual ownership of health.

“Randox is committed to providing accessible and affordable testing to drive significant health improvements through the early detection and prevention of disease. ‘Our Future Health’ is perfectly aligned with that vision.”

Members of the public who are interested in taking part in Our Future Health later this year can register for news and updates  at www.ourfuturehealth.org.uk

 

For more information contact:
Mia Taylor
mia.taylor@woburnpartners.com
+44 (0) 7891525749
James Robinson
james.robinson@woburnpartners.com

Want to know more?

Contact us

Related Pages

ABOUT RANDOX

NEWS

VACANCIES

OUR PEOPLE


VeraSTAT – Enquiry

Excellence at the point of care, with accurate results in minutes


Largest COVID PCR testing provider announces new nationwide network of ‘adaptive’ labs

COVID-19 Testing        News        Contact Us

Tuesday 28 September 2021:  Largest COVID PCR testing provider announces new nationwide network of ‘adaptive’ labs

Randox, the UK’s largest laboratory diagnostics company, today announces its most significant expansion to date – the opening of 10 new adaptive “cube” laboratories within Great Britain. These facilities provide a rapid and cost-effective model to expand laboratory provision.   They will improve accessibility to Covid testing, facilitate wider screening services and adapt to future health and testing challenges.  Based on a modular format, sites can be operational within weeks and be redeployed if required.

The laboratories will initially be used to enhance the UK’s COVID-19 testing capacity during the winter, with each lab’s daily capacity of 12,000 tests combining to bring online an additional 120,000 COVID samples per day.  They can subsequently be re-purposed to meet the UK’s post COVID diagnostic requirements.

The opening of the new laboratories, which upon completion, will create 700 new jobs across the UK, follows £30 million of investment by Randox, bringing its total COVID-19 investment to £150 million. Two of Randox’s ten new labs are already operational outside Manchester, with two sites to the north of London opening before the end of the month. Following this, a further six labs are set to open by the end of 2021.

Commenting on the announcement Dr Peter FitzGerald, Randox Managing Director, said;

“Whilst the initial emphasis of these new laboratories will be on providing accessible, reliable and cost-effective COVID PCR tests, we of course acknowledge the positive steps being taken to ease restrictions and continue opening up our economy.

“We can draw on what we have learnt both pre and during COVID, leveraging the extensive logistics framework and IT infrastructure we have put in place, to directly address the global shortfall in laboratory testing capacity that has been exposed by the pandemic.

“The time taken to establish the required diagnostic infrastructure in the early stages of the pandemic adversely impacted the international response, but with such an adaptable capability, the UK can, as and when needed, respond rapidly to ever-increasing diagnostic demand.”

The new adaptive laboratories from Randox will ensure the provision of travel testing for those who still require them, and can also support any surge testing for the UK’s National COVID Testing Programme; Randox has processed and reported over 18 million COVID PCR samples to date.  Randox also facilitate Covid-19 lateral flow testing.

Having used its 40 years’ experience in diagnostics to focus the business towards COVID testing and support the fight against the virus, Randox, established in 1982, will subsequently use its new lab sites to service a wider UK system of walk-in clinics which can offer whole-body diagnostic screening programmes.

Dr FitzGerald continued;

“The legacy of COVID is that people increasingly understand and appreciate the importance of diagnostics and testing across our society, and as such we anticipate a real appetite from people to take greater interest in their health.

“We will continue COVID testing where necessary but will harness this high-volume testing capacity to pivot back to our core business offering of clinical health tests. The investment we have made in COVID lab facilities will allow us to build a national testing network that will facilitate a shift towards a new era of preventative healthcare, in which ill-health and disease are detected at the earliest possible opportunity, potentially even before symptoms appear.

“Our new adaptive laboratories will fundamentally be a game-changer for the UK’s future diagnostics requirements – improving patient outcomes and reducing the burden on healthcare services.”

 

For further information on Covid testing services please contact the Randox Covid Customer Support team on covidcustomersupport@randox.com  or +44 (0) 28 9434 3005.

Want to know more?

Contact us or visit Randox Health.

Related COVID-19 Products and Services

PRE DEPARTURE

ANTIBODY TEST

DAY 2 TEST

LABORATORY TOOLS


Emerging SARS-CoV-2 variants: successful detection despite virus mutation

Randox Logo

02 February 2021

Test performance not affected by mutation found in new UK, South African and Brazilian variants.

The new SARS-CoV-2 variants that have been identified recently in the UK (known as 501Y.V1, VOC202012/01 or B.1.1.7 lineage), South Africa (known as 501Y.V2 or B.1.351 lineage) and Brazil (B.1.1.248 lineage), contain multiple mutations in the segment of the virus’ genome that codes for the spike protein.

Of particular interest is a double deletion at position 69-70 of the spike protein gene (69-70del), observed in the B1.1.7 variant, which has been found to affect the performance of some diagnostic PCR assays that use an S gene target (S gene dropout).

Detection of SARS-CoV-2 using the multiplex RT-qPCR assay from Randox Laboratories Ltd. is not affected by the identified mutations. This kit is a fast and highly sensitive multiplex diagnostic solution containing the necessary components to provide the detection of two genes (ORf I ab, E gene) to reduce the impact of genetic variation in the SARS-CoV-2 genome. The multiplex primer mix in this assay allows the amplification of specific gene sequences found within the genome of the pathogen, covering all variants. Therefore, the mutations in the B.I.I.7, B.I.351 and B.I.I.248 lineage variants do not affect the detection of SARS-CoV-2 by the PCR test.

Randox Laboratories Ltd. monitors SARS-CoV-2 variants in NCBI and GISAID databases and performs bioinformatics analysis regularly. Based on in silico analysis the performance of the test is not impacted by the mutations.

The Randox multiplex RT-qPCR diagnostic kit supports clinical and public health laboratories to quickly diagnose COVID-19 caused by SARS-CoV-2 infection, assisting the screening and isolation of individuals that require quarantine and immediate intervention.

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Randox launches new COVID-19 testing facility at Heathrow Airport

Randox launches new COVID-19 testing facility at Heathrow Airport

27 January 2021: Randox launches new COVID-19 testing facility at Heathrow Airport

Global healthcare diagnostics company Randox Health has announced a new COVID-19 testing facility at Heathrow Airport.

The service from Randox, which is the largest COVID-19 testing provider in the UK and Ireland, and a partner in the UK Government’s National COVID-19 Testing Programme, uses gold standard PCR technology to generate results in 1 – 3 hours.

The laboratory is capable of processing up to 1000 samples per day, for both fit to fly and test to release, which allows individuals in England returning home from international travel to stop self-isolating if they get a negative test result after 5 days.

Dr Peter FitzGerald, Randox Founder and Managing Director commented;

“We continue to expand our portfolio of bespoke testing products and services, and our new testing facility at Heathrow Airport brings us one step closer to a timely return to a more normal society.

“It’s great to be able to provide our fit to fly and test to release services to the airport and help support their enormous efforts to restore public confidence in international travel and get people back in the air again.”

The Randox testing facility at Heathrow Airport runs in partnership with Doctap who provide a team of certified Sample Collection Officers to perform the swabbing on site.

A Laboratory Technician subsequently expedites the sample and reports the results, meaning that a fit to fly or test to release certificate that would normally take up to 48 hours now takes as little as 1 hour, and no longer than 3 hours to deliver a certificate back to a customer.

To book a test please visit Doctap.co.uk/randox or check out our London PCR Travel Test Sites here.

For further information on the Mobile Testing Laboratory please email mobiletesting@randox.com

 

Randox Health offers a range of COVID-19 testing services for fit to fly, test to release, workplace testing or simply for peace of mind.

Order a home sample collection kit, book an appointment at a Randox Health Travel Centre (available in the UK and Ireland) or visit a Randox Mobile Laboratory (located at Heathrow and Liverpool Airports).

COVID-19 antibody testing is available in Randox Health Clinics.

 

 

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Randox approved for COVID-19 test to release scheme

RANDOX approved for COVID-19 test to release

21 December 2020: RANDOX approved for COVID-19 test to release

Randox has been added to the Department of Health and Social Care’s list of private providers of coronavirus testing.

This includes the lists for both general testing and test to release, a scheme which is applicable to those in England who need to self-isolate on their return from international travel.

If after 5 days you take a test and receive a negative result, you can stop self-isolating.

To purchase your COVID-19 test kit for test to release, visit; https://www.randoxhealth.com/covid-19-home-testing-kit-2/

Please Note: The earliest you can take the test is 5 full days after you left the country not on the travel corridor list. Individuals who do not opt into the Test to Release scheme will need to self-isolate until 10 full days have passed since they were last in a country not on the travel corridors list.

To opt into the scheme, visit https://www.gov.uk/provide-journey-contact-details-before-travel-uk

You must complete this form within 48 hours of arriving back in the UK and will require your booking reference number and name of the test provider.

To view the list of test and release testing providers, visit; https://www.gov.uk/government/publications/list-of-private-providers-of-coronavirus-testing/list-of-private-providers-of-coronavirus-testing

It is important to keep up to date with government guidelines by visiting https://www.gov.uk/guidance/travel-advice-novel-coronavirus to find out more.

For further information please contact covidcustomersupport@randox.com

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Randox launches Mobile COVID-19 Lab for Workplace Testing

Randox launches Mobile COVID-19 Lab for Workplace Testing

11 December 2020: Randox launches Mobile COVID-19 Lab for Workplace Testing

World-leading diagnostics company Randox Laboratories has today unveiled a new Mobile Laboratory Service which will offer rapid and reliable COVID-19 workplace testing.

The service from Randox, which is the largest COVID-19 testing provider in the UK and Ireland, and a partner in the UK Government’s National COVID-19 Testing Programme, uses gold standard PCR technology to generate results in 1 – 3 hours.

Each Mobile Laboratory will be capable of processing up to 1000 samples per day, to allow employers to uphold COVID safety within the workplace and maintain maximum output.

Dr Peter FitzGerald, Randox Managing Director, said;

“As the nation continues to navigate the working challenges caused by the COVID-19 pandemic, an increasing number of organisations will want to implement a COVID-19 testing regime so that they can sustain safe working environments.

 “With this in mind we continue to expand our portfolio of bespoke testing products and services, and our latest addition, the Mobile Testing Laboratory, in conjunction with our work within the National Testing Programme, brings us one step closer to a timely return to a more normal society.”

As part of the Randox Mobile COVID-19 testing service, a team of healthcare professionals will collect the samples on site, and a Laboratory Technician will subsequently expedite the sample and reports the results.

The Mobile Laboratory is available across the UK from 14th December 2020.

Dr FitzGerald continued;

“Since a new study by researchers at the University College London revealed that 86% of people who tested positive for COVID-19 did not have virus symptoms1, frequent screening of asymptomatic patients, is vital to identify any hotspots and limit further spread.

 “Our Mobile COVID-19 Laboratory, which uses gold standard PCR technology and can visit the location of your choice for immediate service, will promote safe working practices, allow companies to demonstrate their commitment to their staff, and facilitate recovery of the UK economy.”

The Randox Mobile COVID-19 Laboratory comes fully staffed and stocked for testing, and is suitable for any and all industries – Construction, Aviation, Hospitality, Retail and more.

Find out more at https://www.randoxhealth.com/mobile-covid-19-testing-laboratory/

For further information please email mobiletesting@randox.com

 

References

    1 https://www.ucl.ac.uk/news/2020/oct/symptoms-covid-19-are-poor-marker-infection  

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our COVID-19 Products and Services

    HOME TEST

    ANTIBODY TEST

    TRAVEL CERTIFICATE

    LABORATORY TOOLS


    Randox launches €99 Express COVID-19 Testing Service at Dublin Airport

    Randox launches €99 Express COVID-19 Testing Service at Dublin Airport

    16 November 2020: Randox launches 99 Express COVID-19 Testing Service at Dublin Airport

    A 99 Express COVID-19 Testing Service which launches this week in a new Travel Testing Centre at Dublin Airport, will see the creation of 50 new jobs.

    The testing service from Randox, a laboratory partner in the UK’s National COVID-19 Testing Programme, utilises a robust and reliable method of testing known as PCR, which Junior Minister for Transport Hildegarde Naughton described as “the gold standard” for travel testing.

    The launch of the Randox Health Travel Centre, which offers rapid next day delivery of results for pre-departure screening as well as on-arrival testing to reduce quarantine timeframes, comes just after Ireland aligned itself with the new EU ‘traffic light’ system to co-ordinate international travel, on Sunday 8th November.

    Sophie Boyd, Project Manager for the Randox Express COVID-19 Testing Service, explained;     

     “With the introduction of the new EU traffic lights system, some people will need a COVID-19 test before travelling or equally, will want a negative test result simply for their peace of mind.

    “We are delighted to have secured a location at Dublin Airport, that allows us to extend our rapid and reliable COVID-19 Testing Service, already used by a range of well-known companies, airlines and elite sporting organisations, to individual passengers and consumers.”

    The Irish Government has agreed that, whilst those arriving from red zones currently have to quarantine for 14 days, this could soon be waived following a negative result from a COVID-19 PCR test taken five days after arrival in Ireland.

    Sophie continued;

    “Travel requirements during the pandemic continue to evolve, but with the introduction of the EU traffic light system, a common prerequisite to travel or to shorten existing quarantine periods will be a negative PCR COVID-19 test, which is currently the only method of COVID-19 testing recognised and approved by every country worldwide.

    “With significant capacity in place to implement high volume PCR testing, we welcome the opportunity to bolster the travel industry’s enormous efforts to restore public confidence in international travel.

    “We are committed to providing the most cost-effective and accurate test in the market to assist with the normalisation of travel, and so Randox will be opening a number of regional travel centres across Ireland over the coming weeks.”

    Dublin Airport Managing Director Vincent Harrison said the health and safety of passengers and staff had been the airport’s key priority during the pandemic and that continued to be the case;

    “We continue to operate a range of globally-recognised COVID-19 safety measures for the health and wellbeing of all airport visitors, and with the official opening of the Randox Health Travel Centre at Dublin Airport we can further support our passengers by offering them access to testing facilities onsite at the airport.”

    The Randox €99 Express COVID-19 Testing Service is open to all asymptomatic individuals and operates from the Randox Health Travel Centre beside Terminal 2 at Dublin Airport, as well as at a testing facility in Leopardstown Dublin.

    In the coming weeks Randox Health Travel Centres will also open in Galway, Limerick and Cork.

    Visit booking.randox.ie to book your appointment.

    For further information please email info@randoxhealth.com or phone 0800 2545 130.

       

      Want to know more about Randox?

      Contact us or visit our homepage to view more.

      Our COVID-19 Products and Services

      HOME TEST

      ANTIBODY TEST

      TRAVEL CERTIFICATE

      LABORATORY TOOLS


      New Express COVID-19 Testing Service with next day results launched in Dublin

      New Express COVID-19 Testing Service with next day results launched in Dublin

      06 November 2020: New Express COVID-19 Testing Service with next day results launched in Dublin

      A new express COVID-19 testing service has now launched in Ireland, with a rapid next day delivery of results.

      From global diagnostics provider Randox, a laboratory partner in the UK’s National COVID-19 Testing Programme, the service utilises a robust and reliable method of testing known as PCR, the only method recognized and approved for travel testing.

      The PCR testing, which Junior Minister for Transport Transport Hildegarde Naughton described as “the gold standard,” is available in Dublin for pre-travel clearance, or simply for those wanting a COVID-19 test for peace of mind.

      Sophie Boyd, Project Manager for the Randox Express COVID-19 Testing Service, explained;     

       “We appreciate that many people will want a COVID-19 test before travelling home this Christmas, or equally, will want a negative test result to reduce quarantine times and enable them to spend more time with loved ones.

       “PCR testing is currently the only method of COVID-19 testing which is recognised by every country worldwide. Our rapid, accurate and reliable testing service, used already by a range of well-known companies, airlines and elite sporting organisations, will help get plans off to a hassle-free start for travellers and non-travellers alike.”

      The launch of the Randox testing service comes just as Ireland aligns itself with the new EU ‘traffic light’ system to co-ordinate international travel, on Sunday 8th November.

      The Government has agreed that, whilst those arriving from red zones currently have to quarantine for 14 days, this could soon be waived following a negative test result from a COVID-19 test taken five days after arrival in Ireland.

      Sophie continued;

      “Travel requirements during the pandemic continue to evolve, but with the introduction of the EU traffic light system, a common prerequisite will be a negative PCR COVID-19 test prior to travel or to shorten quarantine periods.

      “We have significant capacity in place to implement high volume testing and with our PCR testing service, we look forward to supporting the travel industry’s enormous efforts to restore public confidence in international travel.”

      The Randox Express COVID-19 Testing Service is priced at €99, is open to all asymptomatic individuals and operates from the Clayton Hotel in Dublin.

      Visit booking.randox.ie to book your appointment.

      For further information please email info@randoxhealth.com or phone 0800 2545 130.

        Want to know more about Randox?

        Contact us or visit our homepage to view more.

        Our COVID-19 Products and Services

        HOME TEST

        ANTIBODY TEST

        TRAVEL CERTIFICATE

        LABORATORY TOOLS


        Request a meeting
        ×
        Make an Enquiry - RX series
        ×
        Make an Enquiry - Reagents
        ×
        Kit Insert Request - Reagents
        • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
        ×
        Kit Insert Request - Reagents
        • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
        ×
        Make an Enquiry - Reagents
        ×
        Make an Enquiry - Quality Control
        ×
        Make an Enquiry - RIQAS
        ×
        Make an Enquiry - RIQAS
        ×
        Make an Enquiry - Quality Control
        ×
        Make an Enquiry
        • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
        ×
        Make an Enquiry - Biochip
        • This field is for validation purposes and should be left unchanged.
        ×
        Make an Enquiry - Molecular
        • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
        • This field is for validation purposes and should be left unchanged.
        ×
        Make an Enquiry - Future Diagnostics
        ×
        Make an Enquiry - RX series (Product)
        ×
        Make an Enquiry - Quality Control
        • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
        ×
        Make an Enquiry - RIQAS
        • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.